Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis.

Pregnancy in multiple sclerosis (MS) patients is associated with a lower risk of progression and lower rate of exacerbation. These beneficial effects are reversed postpartum. Considering that the pathogenesis of MS appears to involve cell-mediated immune reactivity, and that pregnancy is accompanied by a depressed cell-mediated immunity, it has been proposed that the lower relapse rate and risk of progression of MS during pregnancy may be due to a pregnancy-associated down-regulation of cell-mediated immunity. In addition, pregnancy results in a shift towards a T helper (Th) 2 cytokine profile, which is presumably protective for MS. This study was aimed at investigating the relationship between clinical status of MS and cytokine levels in eight patients with MS who were followed through pregnancy and after delivery. Peripheral blood lymphocytes from these women were stimulated with a mitogen at different time points during and after gestation and the levels of Th1 cytokines (IFNgamma, TNFalpha) and Th2 cytokines (IL-4, IL-10) were estimated by ELISA. It was established that six of the eight MS patients studied showed a distinct shift from a Th2 cytokine bias during pregnancy towards a Th1 cytokine bias after delivery. These results suggest a possible association between decreased incidence of exacerbation of MS in pregnancy and a pregnancy-induced shift towards Th2 cytokine bias.

Comparison of the cellularity and presence of residual leukemia in bone marrow aspirate and biopsy specimens in pediatric patients with acute lymphoblastic leukemia (ALL) at day 7-14 of chemotherapy.

BACKGROUND: Many pediatric chemotherapy protocols for treatment of ALL require a bone marrow examination at day 7 or day 14 after initiation of therapy. The usefulness of a bone marrow biopsy, in addition to an aspirate, has been a frequently asked question. PROCEDURE: This study addresses the evaluation of bone marrow cellularity and presence of residual leukemia in both aspirate and biopsy specimens in 45 consecutive pediatric patients (ages 1-19 years, 19 females, and 26 males) with ALL 7-14 days after initiation of therapy. DISCUSSION: 20/45 patients showed evidence of residual leukemia by bone marrow biopsy; 16/20 (80%) of these had evidence of residual leukemia in the aspirate specimen. Of the 4 aspirate specimens that did not demonstrate residual leukemia, 2 had <5% blasts and 2 had too few cells in the aspirate for evaluation. Of the 25/45 bone marrow biopsy specimens with no detectable residual leukemia, 14 of the aspirates had <5% blasts, and 11 had too few cells in the aspirate for evaluation. 13/45 (29%) of the aspirates had too few cells for a differential count. The bone marrow cellularity judged from the aspirate specimen was considered to be low (0-1+) in 34/45 patients. Of these 34 patients, the bone marrow biopsy showed hypocellularity (<20% cellularity) in 12/34, moderate cellularity (20-79% cellularity) in 14/34, and hypercellularity (>79% cellularity) in 8/34. CONCLUSIONS: We conclude that both the bone marrow aspirate and biopsy specimens provide important information in evaluating the response to chemotherapy in pediatric patients with ALL at day 7-14 of induction chemotherapy. The aspirate alone may be misleading in terms of cellularity in many patients and may not provide evidence of residual leukemia.

Benign breast aspirates: two decades of experience.

OBJECTIVE: To evaluate the reliability of benign breast aspirates. DESIGN: A 20-year retrospective study of cytologically benign aspirates from palpable breast lesions followed by surgery and review of false negatives. RESULTS: Data encompassed 1518 benign aspirates followed by benign histology, and 99 by malignant histology. Of the latter, 89% underwent biopsy within 1 month. Review of 52 available false negatives revealed 10 (19%) with no change in the original diagnosis, 16 (31%) reviewed as unsatisfactory specimens, and 26 (50%) reviewed as specimens with focal cytologic atypia (dyshesion, nuclear enlargement, and contour irregularity). Cellularity (>20 epithelial groups per slide) was an important criterion in postmenopausal women. CONCLUSION: Our study confirms the reliability of benign breast aspirates interpreted in light of clinical and mammographic findings and demonstrates the importance of adequacy evaluation and focal atypia in preventing false negatives.

Postmenopausal squamous-cell atypias: a diagnostic challenge.

Exfoliative cytologic studies directed toward atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) have been neglected in the rising postmenopausal population. This retrospective study from 60 cases, initially interpreted as ASCUS or LSIL, concentrates on these lesions and their associated diagnostic pitfalls. Cytologic reevaluation of the 60 patients revealed squamous-cell abnormalities in 45 (18 ASCUS and 27 LSIL) and cervicitis alone in 15 cases. Follow-up studies of the 18 ASCUS cases showed cervicitis in seven, persistent ASCUS in five, CIN I in five, and VAIN I-II in one. Follow-up of the 27 cases categorized as LSIL, showed ASCUS in two, CIN in 20 and VAIN in one, while four had cervicitis alone. Interestingly, two of these 45 patients had only vaginal dysplasia. By application of uniform diagnostic criteria, 15 of the 60 cases were reviewed as benign. Pitfalls included inflammatory and drying alterations, reactive metaplasia, and sampling problems. Thus, squamous-cell abnormalities in postmenopausal women can be significant when artifactual alterations are eliminated.